<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898610</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004505-16</org_study_id>
    <nct_id>NCT02898610</nct_id>
  </id_info>
  <brief_title>Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke</brief_title>
  <acronym>CONVINCE</acronym>
  <official_title>CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic Stroke) - a Randomised Clinical Trial of Low-dose Colchicine for Secondary Prevention After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Irish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Limerick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University of Ireland, Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitat de Lleida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of Colchicine in adults over 40 years of age who have suffered
      an ischaemic stroke or transient ischaemic attack NOT caused by cardiac embolism or other
      defined causes. Patients will be randomised to 0.5 mg/day of Colchicine plus usual care, or
      to usual care alone.

      To investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (defined as
      antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice)
      compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial
      infarction, cardiac arrest, hospitalization for unstable angina and vascular death after
      ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other
      defined causes unrelated to atherosclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inflammation is a key pathophysiological contributor to unstable atherosclerotic plaque and
      thrombo-embolic events, stroke, myocardial infarction, and vascular death. Internationally,
      clinical trials are targeting atherosclerotic inflammation in patients with coronary disease
      using methotrexate, colchicine, and canukinumab.

      Aims:

      The primary aim is to compare low-dose colchicine (0.5mg/day) plus usual care, to usual care
      alone, to prevent non-fatal recurrent ischaemic stroke and coronary events and vascular death
      after non-severe, noncardioembolic TIA/stroke. Secondary objectives will investigate safety
      of low-dose colchicine, and efficacy for each component of the primary outcome, fatal and
      non-fatal events, disabling and non-disabling stroke, effect modification by prespecified
      subgroups, and impact on direct health care costs, adjusted for quality-adjusted life years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 12, 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of non-fatal ischemic stroke</measure>
    <time_frame>any time within 60 month</time_frame>
    <description>Any recurrence of non-fatal ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>on-fatal Major Cardiac event</measure>
    <time_frame>any time within 60 months</time_frame>
    <description>Non-fatal hospitalization for unstable angina, myocardial infarction, cardiac arrest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular death</measure>
    <time_frame>60 months</time_frame>
    <description>Fatal ischemic stroke, myocardial infarction, cardiac arrest</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2623</enrollment>
  <condition>Ischemic Attack, Transient</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Colchicine treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 0.5mg/day plus usual care for 60 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Standard of care alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal standard of care remains for these patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <arm_group_label>Colchicine treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent consistent with ICH-GCP guidelines and local laws signed
             prior to all trial-related procedures.

          2. Age 40 years or greater

          3. Either,

               -  ischaemic stroke without major disability (modified Rankin score 3 or less)

               -  or high-risk TIA

          4. Qualifying stroke/TIA probably caused by large artery stenosis, small artery occlusion
             (lacunar stroke), or cryptogenic embolism, with cardiac embolism or other defined
             stroke mechanism deemed unlikely in the opinion of the treating physician.

          5. GFRgreater than or equal to 50 ml/min.

          6. In the opinion of the treating physician, patient is medically-stable, capable of
             participating in a randomised trial, and willing to attend follow-up.

        Exclusion Criteria:

          1. Cardio-embolic stroke/TIA, probably caused by identified atrial fibrillation
             (permanent or paroxysmal), in the opinion of the treating physician.

          2. Cardio-embolic stroke/TIA probably caused by other identified cardiac source
             (intra-cardiac thrombus, endocarditis, metallic heart valve, low ejection fraction
             &lt;30%), in the opinion of the treating physician.

          3. Stroke/TIA caused by dissection, endocarditis, paradoxical embolism, drug use, venous
             thrombosis, within 48 hours aftercarotid or cardiac surgery, hypercoagulability
             states, migraine, or inherited cerebrovascular disorders (eg. Fabry's disease,
             CADASIL), in the opinion of the treating physician.

          4. History of myopathy or myalgias with raised creatine kinase (CK) on statin therapy.

          5. Blood dyscrasia defined as anaemia (haemoglobin &lt;10g/dL), thrombocytopenia (platelet
             count &lt;150 x109/L) or leucopenia (white cell count &lt;4 x109/L) at randomisation.

          6. Impaired hepatic function (transaminases greater than twice upper limit of normal) at
             randomisation.

          7. Concurrent treatment with moderate or strong CYP3A4 inhibitors (clarithromycin,
             erythromycin, telithromycin, other macrolide antibiotics, ketoconazole, itraconazole,
             voriconazole, ritonavir, atazanavir, indinavir, other HIV protease inhibitors,
             verapamil, diltiazem, quinidine, digoxin, disulfiram) or P-gp inhibitors
             (cyclosporine) at randomisation.

          8. Symptomatic peripheral neuropathy and pre-existing progressive neuromuscular disease

          9. Inflammatory bowel disease (Crohn's or ulcerative colitis) or chronic diarrhoea.

        9. Dementia, sufficient to impair independence in basic activities of daily living.

        10. Active malignancy, known hepatitis B or C, or HIV infection prior to qualifying
        stroke/TIA.

        11. Impaired swallow preventing oral administration of study medication. 12. History of
        poor medication compliance. 13. Unlikely to comply with study procedures and follow-up
        visits due to severe or fatal comorbid illness or other factor (eg. inability to travel for
        follow up visits), in opinion of randomising physician.

        14. Pregnancy, breast-feeding, or pre-menopausal women 15. Patient concurrently
        participating in another clinical trial with an investigational drug or device, or use of
        investigational drug within 30 days or 5 half-lives before the Screening visit (whichever
        is longer) 16. Known allergy or sensitivity to colchicine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Peter Kelly</last_name>
    <role>Study Director</role>
    <affiliation>Mater Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prof Peter Kelly</last_name>
    <email>isctn@ucd.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof Sean Murphy</last_name>
    <email>isctn@ucd.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Geert Vanhooren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peter Vanacker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC Leige</name>
      <address>
        <city>Leige</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Desfontaines</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robin Lemmens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon Cronin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Letterkenny University Hospital</name>
      <address>
        <city>Donegal</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Miranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connolly Hospital, Blanchardstown</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eamon Dolan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Murphy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joe Harbison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Cassidy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Adelaide &amp; Meath Hospital, Dublin incorporting the NCH</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronan Collins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin O'Donnell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naas General Hospital</name>
      <address>
        <city>Kildare</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paul OBrien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John McManua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes, Drogheda</name>
      <address>
        <city>Louth</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Mulroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo University Hospital</name>
      <address>
        <city>Mayo</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tom O'Malley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sligo University Hospital</name>
      <address>
        <city>Sligo</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paula Hickey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tipperary General Hospital, Clonmel</name>
      <address>
        <city>Tipperary</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Donnellan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Pope</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joan Marti Fabgreas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elisa Cuadrado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francisco Purroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Ireland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A summary report of the trial will be provided to the Ethics Committees and relevant Regulatory Authority within as per national legal requirements in participating countries</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

